Cursor is nearing a funding round of at least $2 billion, with returning investors Thrive and Andreessen Horowitz expected to lead the financing at a $50 billion valuation. The deal terms are not final and may still change.
Goldman Sachs' Chief Equity Strategist Peter Oppenheimer has called the recent sell-off in U.S. tech stocks a rare 'buying opportunity,' suggesting that the current market conditions may favor investment in this sector.
Awards may be encouraging and occasionally useful for visibility, but they are weak indicators of validation and poor predictors of long-term success. In the longevity and healthspan industry, where timelines are long and claims are easy to overstate, venture capital ultimately follows alignment and evidence, not applause received at glitzy industry events.
Helical's thesis is that bio foundation models, AI systems trained on vast genomic, transcriptomic, and proteomic datasets, have already crossed a quality threshold that makes computational hypothesis-testing meaningful in pharma research.
Raising venture capital too early can cost you control, leverage and even your company. Early capital is often highly dilutive, selling off your future before your blueprint is complete. The difference between lighting a spark and burning your equity to ash is a lesson many founders learn too late.
Because startups typically don't have a track record of success to attract potential clients, they can offer a trial of their platform for free or at a lower cost to showcase what their platform can do and how reliable it is. The enterprise - a potential client - can test the newest technologies without the worry of committing to a complete and often costly rollout.
ADIN uses AI to replace the human analysts involved in venture dealmaking. Put in a startup's pitch deck, and out comes a detailed analysis of its business model and founding team, a list of diligence questions and compliance risks, an estimate of the total addressable market, and a suggested valuation. ADIN has about a dozen different agentic investors, each with a distinct persona and investing thesis.
